Abbott Yields To Brazil Pressure, Avoids Compulsory License On Kaletra
In a last-minute compromise that averted a compulsory license, U.S. drug maker Abbott Laboratories agreed Friday to lower the price the Brazilian government pays for its AIDS drug Kaletra....To view the full article, register now.
Already a subscriber? Click here to view full article